Making the Decision: Can Physician-Owned Orthopedic ASCs Remain Independent?
According to Mr. Fink, there are several challenges facing ASCs, including market saturation, migration of surgeons to hospital employment and more stringent physician requirements.
From physician ASC-owner perspective, these five factors affect the viability of remaining independent, according to Mr. Fink and Mr. Feldman:
1. The physician and procedure/payer mix.
2. The managerial capability and efficiency at the center.
3. Contracting initiatives and whether a center has the capability to incorporate new reimbursement models, such as bundled payments.
4. Dependence on out-of-network revenues, as this is no longer a viable strategy.
5. Patient satisfaction rates as well as quality and outcomes reporting.
Another important factor is succession planning at the center, notes Mr. Feldman. It is helpful if ASC administrators are involved in this process. "I try and stay involved by meeting with new physicians coming into the center," he said. "I also share the financial and operational goals of the center with them."
However, there are situations in which ASCs might need to think about partnering with a hospital. "Physician-owned orthopedic ASCs might want to consider partnering with a hospital if they have high-cost environmental or capital needs, are having difficulty recruiting new investors, an increasing presence of narrow networks/ACOs and margins reliant on out-of-network strategy," said Mr. Fink.
More Articles on ASCs:Dr. Daniel Eglinton Opens Asheville Biologics and Orthopedics
Who's Buying? 5 Statistics on ASC Acquisitions in 2010 vs. 2013
7 Things for ASC Leaders to Know for Thursday
© Copyright ASC COMMUNICATIONS 2016. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- This peptide may treat bacterial infections: 3 study insights
- Crohn's & Colitis Foundation shares results from IBD Qorus pilot program: 3 notes
- Patients over 75 years old may not benefit from colonoscopy: 4 study insights
- FDA approves Janssen Biotech's STELARA; Boston Scientific leads GI/endoscopic device market & more: 7 GI company key notes
- Outpatient hip resurfacing lowers cost up to 60%: 5 study insights